Travel time may impact breast cancer treatment completion

NCT ID NCT07527741

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 4 times

Summary

This study looks at how the location of treatment affects whether people with early-stage HER2-positive breast cancer stick to their therapy plan. Researchers will compare patients who have to travel far for treatment with those who don't. The goal is to see if making treatment more local helps people complete their full course of care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EARLY STAGE HER2+ BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • General Hospital "Dr Laza K. Lazarevic" Sabac

    RECRUITING

    Šabac, Popa Karana 2-4, 15000, Serbia

  • General Hospital ''Stefan Visoki'' Smederevska Palanka

    RECRUITING

    Smederevska Palanka, Vuka Karadžića 147, 11420, Serbia

  • General Hospital Pančevo

    RECRUITING

    Pančevo, Miloša Trebinjca 11, 26000, Serbia

  • General Hospital Požarevac

    RECRUITING

    Požarevac, Bratstva Jedinstva 135, 12000, Serbia

  • Health Centre ''Sveti Luka'' Smederevo

    RECRUITING

    Smederevo, Knez Mihailova 51, 11300, Serbia

  • Health Centre Kladovo

    RECRUITING

    Kladovo, Dunavska 1-3, 19320, Serbia

  • Health Centre Loznica

    RECRUITING

    Loznica, Bolnička 65, 15300, Serbia

  • Health Centre Valjevo

    RECRUITING

    Valjevo, Sinđelićeva 62, 14000, Serbia

  • Healthcare Centre Bor

    RECRUITING

    Bor, Dragiše Mišovića 1, 19210, Serbia

  • Institute for Onocology and Radiology of Serbia

    RECRUITING

    Belgrade, Pasterova 14, 11000, Serbia

More trials for these conditions

Other studies related to the condition(s) this trial covers.